Barbara A. Parker

ORCID: 0000-0003-0499-1289
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer Genomics and Diagnostics
  • Cancer survivorship and care
  • Cancer Risks and Factors
  • Cancer-related cognitive impairment studies
  • Breast Cancer Treatment Studies
  • BRCA gene mutations in cancer
  • Lung Cancer Treatments and Mutations
  • Genetic factors in colorectal cancer
  • Circadian rhythm and melatonin
  • Childhood Cancer Survivors' Quality of Life
  • Estrogen and related hormone effects
  • Cancer Cells and Metastasis
  • Nutritional Studies and Diet
  • Nutrition and Health in Aging
  • Global Cancer Incidence and Screening
  • Cancer Treatment and Pharmacology
  • Statistical Methods in Clinical Trials
  • Nutrition, Genetics, and Disease
  • Mobile Health and mHealth Applications
  • Metabolism, Diabetes, and Cancer
  • HER2/EGFR in Cancer Research
  • Advanced Breast Cancer Therapies
  • Colorectal Cancer Treatments and Studies
  • Lymphoma Diagnosis and Treatment
  • Economic and Financial Impacts of Cancer

University of California, San Diego
2016-2025

Moores Cancer Center
2012-2024

UC San Diego Health System
2015-2024

University of California, San Francisco
2013-2023

UC Irvine Health
2021

Health Net
2021

University of South Australia
2019

University of California, Los Angeles
2015-2018

University of California, Davis
2008-2018

La Jolla Alcohol Research
2015-2018

We have examined the discrete species of simian virus 40 (SV40) RNA present very early in infection monkey cells with wild-type virus, mutant tsA58 and corresponding DNAs to distinguish between two classes models for control late transcription: (i) positive mediated by large-T antigen (ii) negative a repressor protein associated viral DNA virion. Total cytoplasmic or nuclear polyadenylated RNAs from infected were denatured glyoxal, separated electrophoresis on agarose gels, transferred...

10.1128/jvi.31.2.360-369.1979 article EN Journal of Virology 1979-08-01

Older women with breast cancer are underrepresented in clinical trials, and data on the effects of adjuvant chemotherapy such patients scant. We tested for noninferiority capecitabine as compared standard who were 65 years age or older.We randomly assigned stage I, II, IIIA, IIIB to (either cyclophosphamide, methotrexate, fluorouracil cyclophosphamide plus doxorubicin) capecitabine. Endocrine therapy was recommended after hormone-receptor-positive tumors. A Bayesian statistical design used a...

10.1056/nejmoa0810266 article EN New England Journal of Medicine 2009-05-13

Purpose Single-variable analyses have associated physical activity, diet, and obesity with survival after breast cancer. This report investigates interactions among these variables. Patients Methods A prospective study was performed of 1,490 women diagnosed treated for early-stage cancer between 1991 2000. Enrollment an average 2 years postdiagnosis. Only seven were lost to follow-up through December 2005. Results In univariate analysis, reduced mortality weakly higher vegetable-fruit...

10.1200/jco.2006.08.6819 article EN Journal of Clinical Oncology 2007-06-09

Direct-to-consumer trackers and devices have potential to enhance theory-based physical activity interventions by offering a simple pleasant way help participants self-monitor their behavior. A secondary benefit of these is the opportunity for investigators objectively track adherence goals across weeks or even months, rather than relying on self-report small number accelerometry wear periods. The use consumer continuous monitoring has considerable research, but few studies been published in...

10.2196/mhealth.4229 article EN cc-by JMIR mhealth and uhealth 2015-11-19

Obesity increases risk for all-cause and breast cancer mortality comorbidities in women who have been diagnosed treated cancer. The Exercise Nutrition to Enhance Recovery Good Health You (ENERGY) study is the largest weight loss intervention trial among survivors of date.In this multicenter trial, 692 overweight/obese were, on average, 2 years since primary treatment early-stage were randomly assigned either a group-based behavioral intervention, supplemented with telephone counseling...

10.1200/jco.2015.61.1095 article EN Journal of Clinical Oncology 2015-08-18

Abstract Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is) have revolutionized breast cancer therapy. However, <50% of patients an objective response, nearly all develop resistance during To elucidate the underlying mechanisms, we constructed interpretable deep learning model response to palbociclib, a CDK4/6i, based on reference map multiprotein assemblies in cancer. The identifies eight core that integrate rare common alterations across 90 genes stratify palbociclib-sensitive versus...

10.1038/s43018-024-00740-1 article EN cc-by Nature Cancer 2024-03-05

Abstract Objective : The concept of symptom clusters is relatively new in cancer patients' management. This study, which spanned four cycles chemotherapy, combined three commonly seen pre‐treatment symptoms patients (i.e. sleep disturbances, fatigue and depression) into one cluster, to explore the associations between cluster categories longitudinal profiles these same during chemotherapy. Methods was a prospective study. Seventy‐six women with newly diagnosed stage I–III breast cancer,...

10.1002/pon.1412 article EN Psycho-Oncology 2008-08-01

Abstract Objective. DNA sequencing tests are enabling physicians to interrogate the molecular profiles of patients’ tumors, but most oncologists have not been trained in advanced genomics. We initiated a tumor board provide expert multidisciplinary input for these patients. Materials and Methods. A team that included clinicians, basic scientists, geneticists, bioinformatics/pathway scientists with expertise various cancer types attended. Molecular were performed Clinical Laboratory...

10.1634/theoncologist.2013-0405 article EN The Oncologist 2014-05-05

Self-reported diabetes has been associated with poor breast cancer outcomes. Research is needed to investigate the relationship between biologically determined glycemic control and prognosis.

10.1200/jco.2010.29.3183 article EN Journal of Clinical Oncology 2010-11-30

Abstract By profiling their patients' tumors, oncologists now have the option to use molecular results match patients with drug(s) based on specific biomarkers. In this observational study, 347 solid advanced cancers and next-generation sequencing (NGS) were evaluated. Outcomes for who received a “matched” versus “unmatched” therapy following NGS compared. Eighty-seven (25%) treated therapy, 93 (26.8%) an therapy. More in matched group achieved stable disease (SD) ≥ 6 months/partial response...

10.1158/1535-7163.mct-15-0795 article EN Molecular Cancer Therapeutics 2016-02-13

BACKGROUND Increasing physical activity can improve cognition in healthy and cognitively impaired adults; however, the benefits for cancer survivors are unknown. The current study examined a 12‐week intervention, compared with control condition, on objective self‐reported among breast survivors. METHODS Sedentary were randomized to an exercise arm (n = 43) or 44). At baseline at 12 weeks, was measured National Institutes of Health Cognitive Toolbox, using Patient‐Reported Outcomes...

10.1002/cncr.30987 article EN Cancer 2017-09-19

REPORT insomnia symptoms. 1,2 There is also evidence suggesting that breast cancer patients constitute the subgroup of most at risk for experiencing sleep difficulties. 3,4 In addition to resulting in restless (i.e., increased activity during night), and its treatment may reduce daytime activity.Although data are rather sparse, there some suggest have disturbed circadian rhythms.6][7][8][9] But few examined variables before patients.Some on rhythms be altered even prior initiation...

10.1093/sleep/32.9.1155 article EN SLEEP 2009-09-01

// Maria Schwaederle 1 , Hatim Husain Paul T. Fanta David E. Piccioni Santosh Kesari Richard B. Schwab Kimberly C. Banks 2 Lanman AmirAli Talasaz Barbara A. Parker Razelle Kurzrock Center for Personalized Cancer Therapy and Division of Hematology Oncology, UCSD Moores Center, La Jolla, CA, USA Guardant Health, Inc., Redwood City, Correspondence to: Schwaederle, e-mail: mschwaederle@ucsd.edu Keywords: cancer, liquid biopsy, ctDNA, actionable alteration, personalized therapy Received:...

10.18632/oncotarget.7110 article EN Oncotarget 2016-02-01

Abstract Purpose: There is a growing interest in using circulating tumor DNA (ctDNA) testing patients with cancer. Experimental Design: A total of 168 diverse cancers were analyzed. Patients had digital next-generation sequencing (54 cancer-related gene panel including amplifications ERBB2, EGFR, and MET) performed on their plasma. Type genomic alterations, potential actionability, concordance tissue testing, patient outcome examined. Results: Fifty-eight percent (98/168) ≥1 ctDNA...

10.1158/1078-0432.ccr-16-0318 article EN Clinical Cancer Research 2016-05-17
Coming Soon ...